By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Halozyme Therapeutics, Inc. 

11388 Sorrento Valley Road

San Diego  California  92121  U.S.A.
Phone: 858-794-8889 Fax: 858-259-2539

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at

Key Statistics

Ownership: Public

Web Site: Halozyme
Employees: 152
Symbol: HALO

Company News
Halozyme (HALO) Phase II Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO 6/5/2017 6:25:57 AM
Halozyme (HALO) Announces Completion Of Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares 5/25/2017 7:26:40 AM
Halozyme (HALO) Prices Public Offering Of Common Stock 5/19/2017 6:55:13 AM
Halozyme (HALO) Announces Public Offering Of Common Stock 5/19/2017 6:54:24 AM
Halozyme (HALO) Reports First Quarter 2017 Financial Results 5/10/2017 10:54:24 AM
Halozyme (HALO) CEO: PEGPH20 Bolsters Checkpoint Inhibitors in Preclinical Data 4/6/2017 5:49:50 AM
Halozyme (HALO)'s PEGPH20 Increases Immune Response And Effectiveness Of Immunotherapies In Preclinical Cancer Models 4/3/2017 9:06:10 AM
Halozyme (HALO) Crashed After Enrollment In Early Clinical Trials Have Been Temporarily Suspended 3/30/2017 12:10:20 PM
Halozyme (HALO) Release: FDA Advisory Committee Provides Unanimous Recommendation For Subcutaneous Rituximab Coformulated With Halozyme Enhanze Technology 3/29/2017 9:23:50 AM
Halozyme (HALO) Reports Fourth Quarter And Full Year 2016 Financial Results 3/1/2017 9:15:10 AM